| Identification | Back Directory | [Name]
Urea, N-[(1R)-1-[[(4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-diMethyl-1-piperidinyl]carbonyl]-2-Methylpropyl]-N'-(2-hydroxy-2-Methylpropyl)- | [CAS]
1202400-18-7 | [Synonyms]
CCR1 antagonist 2
1-[(2R)-1-[(4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl]-3-methyl-1-oxobutan-2-yl]-3-(2-hydroxy-2-methylpropyl)urea
Urea, N-[(1R)-1-[[(4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-diMethyl-1-piperidinyl]carbonyl]-2-Methylpropyl]-N'-(2-hydroxy-2-Methylpropyl)- | [Molecular Formula]
C23H36ClN3O4 | [MDL Number]
MFCD25976726 | [MOL File]
1202400-18-7.mol | [Molecular Weight]
454 |
| Chemical Properties | Back Directory | [Boiling point ]
660.7±55.0 °C(Predicted) | [density ]
1.182±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
13.42±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
BMS-817399 is a potent, selective, and orally bioavailable CCR1 antagonist. BMS-817399 exhibits CCR1 binding affinity and chemotaxis inhibition potencies of 1 and 6 nM (IC50), respectively. BMS-817399 can be used for the research of rheumatoid arthritis[1]. | [IC 50]
CCR1: 1 nM (IC50) | [References]
[1] Santella JB 3rd, et al. Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. J Med Chem. 2014;57(18):7550-7564. DOI:10.1021/jm5003167 |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|